(CercleFinance.com) – Denali Therapeutics announced on Friday that it had been informed by its strategic partner Sanofi of the failure of a phase 2 clinical trial in the treatment of amyotrophic lateral sclerosis (ALS).
According to the biopharmaceutical company, SAR443820/DNL788 did not meet its primary efficacy endpoint in the study, which was an improvement in functional scores.
Denali adds that Sanofi plans to present detailed results of the study at an upcoming scientific conference.
The phase 2 study concerning SAR443820/DNL788, a small oral molecule which crosses the blood-brain barrier, is nevertheless expected to continue as planned in multiple sclerosis.
Sanofi and Denali Therapeutics announced in 2018 their intention to jointly develop drugs for the treatment of neurological and inflammatory diseases.
Listed on the Paris Stock Exchange, Sanofi shares fell 0.6% after this announcement. On Wall Street, Denali shares fell more than 7%.